Expression and Functions of the CB2 Receptor in Human Leukocytes.

Abstract

The cannabinoid CB₂ receptor was cloned from the promyeloid cell line HL-60 and is notably expressed in most, if not all leukocyte types. This relatively restricted localization, combined to the absence of psychotropic effects following its activation, make it an attractive drug target for inflammatory and autoimmune diseases. Therefore, there has been an increasing interest in the past decades to identify precisely which immune cells express the CB₂ receptor and what are the consequences of such activation. Herein, we provide new data on the expression of both CB₁ and CB₂ receptors by human blood leukocytes and discuss the impact of CB₂ receptor activation in human leukocytes. While the expression of the CB₂ mRNA can be detected in eosinophils, neutrophils, monocytes, B and T lymphocytes, this receptor is most abundant in human eosinophils and B lymphocytes. We also review the evidence obtained from primary human leukocytes and immortalized cell lines regarding the regulation of their functions by the CB₂ receptor, which underscore the urgent need to deepen our understanding of the CB₂ receptor as an immunoregulator in humans.

Untitled section

Keywords: CB2 receptor, eosinophil, neutrophil, monocyte, lymphocyte, inflammation, asthma, allergy

Article notes

Untitled section

Received 2021 Nov 30; Accepted 2022 Jan 14; Collection date 2022.

Author notes

Introduction

The cannabinoid receptors 1 and 2 (CB₁ and CB₂) are two G protein-coupled receptors that function through binding a vast array of ligands including phytocannabinoids and endocannabinoids (Di Marzo et al., 1998; Turcotte et al., 2015). The CB₁ receptor, highly expressed in the brain, was the first cannabinoid receptor identified through its responsiveness to Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cloned (Devane et al., 1988; Matsuda et al., 1990). Its activation induces psychotropic effects and its involvement shown in, among others, motor function, cognition and memory (Howlett and Abood 2017). It is also widely recognized as worsening obesity and related diseases (Di Marzo 2018). The CB₂ receptor was later cloned from HL-60 cells and identified on its 44% aminoacid homology with the CB₁, as well as its similar binding profile to the endocannabinoid N-arachidonoyl-ethanolamine (AEA) and Δ⁹-THC (Munro et al., 1993). Soon after, Galiègue et al. documented that it was expressed by human leukocytes (Galiegue et al., 1995). This consolidated the concept that the CB₂ is the peripheral cannabinoid receptor and, for many, the inflammatory cannabinoid receptor. In fact, the CB₂ receptor has been found in all leukocyte populations tested so far [see (Turcotte et al., 2016) for a review]. However, CB₂ receptor expression is not restricted to leukocytes. It has notably been found in resident immune brain cells (microglia), the kidney, spleen, tonsil, thymus, lung epithelial cells and testes (Sanchez et al., 2001; Brown et al., 2002; Van Sickle et al., 2005; Ellert-Miklaszewska et al., 2007; Zhou et al., 2018; Cakir et al., 2019; Fantauzzi et al., 2020).

Expression of the CB₁ and CB₂ Receptors by Human Blood Leukocytes

Galiègue et al. paved the way to our understanding of CB₂ expression by human leukocytes by showing its mRNA was expressed in human leukocytes, with the following order of relative abundance: tonsillar B cells > natural killer cells > monocytes ∼ granulocytes > T4 lymphocytes > T8 lymphocytes (Galiegue et al., 1995). While very informative and useful, the data from Galiègue et al. did not include eosinophils while including tissue instead of blood B lymphocytes. This was somewhat pointed out in following studies (Turcotte et al., 2016), as it might have led to some inconsistencies. For example, while some documented the expression of the CB₂ receptor in human granulocytes (neutrophils and contaminating eosinophils) (Galiegue et al., 1995; Kurihara et al., 2006), others did not (Oka et al., 2004; Graham et al., 2010). This raised the possibility that contaminating cells might have been responsible for the previously documented CB₂ signal in neutrophils, and possibly other cell types. Noteworthy, it was later reported that eosinophil-depleted neutrophils weakly expressed the CB₂ receptor mRNA, while eosinophils (the main neutrophil suspension contaminant) expressed it at high levels, raising the strong possibility that discrepancies regarding CB₂ expression in neutrophils could be the result of contaminating eosinophils in granulocyte preparations (Chouinard et al., 2013). CB₂ expression was also reported in human eosinophils in other studies (Frei et al., 2016; Larose et al., 2017; Freundt-Revilla et al., 2018; Dothel et al., 2019).

In an attempt to better define CB₂ expression in human blood leukocytes, we revisited its expression by qPCR using mRNA from leukocytes that were isolated from the blood of healthy volunteers. CB₁ receptor expression was assessed in parallel. Hypothalamus samples were utilized as positive controls for the CB₁ receptor. In our hands, all tested leukocytes expressed the CB₁ receptor mRNA although to a lesser extent than hypothalamus samples (Figure 1A). In contrast, while we detected the expression of the CB₂ receptor mRNA in all leukocyte and hypothalamus samples, human eosinophils and B lymphocytes displayed the strongest signals (Figure 1B). Thus, these cell types are likely the origin of CB₂ expression found in mixed populations such as granulocytes (neutrophils and eosinophils, often abbreviated as PMN) and PBMCs (monocytes, B and T lymphocytes). This underlines the importance of separating granulocytes and PBMCs when studying the CB₂ receptor. The small, but detectable levels of CB₂ receptor mRNA in hypothalamus samples are consistent with other studies reporting its expression in this tissue (Sanchez et al., 2001; Van Sickle et al., 2005; Ellert-Miklaszewska et al., 2007).

Expression of the CB1 and CB2 receptors mRNA in human leukocytes isolated from the blood. Human venous blood was collected from healthy volunteers with the informed consent of all participants in blood collection tubes containing K3EDTA as anticoagulant. Granulocytes (GRAN), eosinophils (EOS) and neutrophils (NEU) were isolated as in Chouinard et al. (2013). PBMCs were obtained from the PBMC layer and taken as is or otherwise processed for monocyte (MONO), B and T lymphocytes (LYMP) isolation using the EasySep™ monocyte isolation kit, CD19 positive Selection Kit II and CD3 positive selection Kit II respectively, as per the manufacturer’s protocol. Purity of the different isolated leukocytes was always >97% with the exception of B Lymphocytes (90%) with MONO being the main contaminant. Hypothalamus (HYPO) samples were obtained from the Douglas-Bell Canada Brain Bank (McGill University, Montréal, Canada). mRNA was next isolated from the different preparations with TRIzol as per the manufacturer’s protocol. 500 ng of total RNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA) as recommended. qPCR analyses were finally performed on a CFX Connect Real-Time PCR System, using the following primers (forward - reverse): GAPDH (5′-ACATCGCTCAGACACCATG-3′–5′-TGTAGTTGAGGTCAATGAAGGG-3′) 18S (5′-CGCACGGCCGGTACAGTGAA-3′–5′-GGGAGAGGAGCGAGCGACCA-3′) CB1 (5′-TTCCCTCTTGTGAAGGCACTG-3′–5′-TCTTGACCGTGCTCTTGATGC-3′) and CB2 (5′-CAAGGCTGTCTTCCTGCTGA-3′–5′-CGGGTGAGCAGAGCTTTGTA-3′). Data represent the mean (±SEM) of 4–6 donors and was obtained using the CFX Maestro Software (Bio-Rad). — FIGURE 1Expression of the CB₁ and CB₂ receptors mRNA in human leukocytes isolated from the blood. Human venous blood was collected from healthy volunteers with the informed consent of all participants in blood collection tubes containing K₃EDTA as anticoagulant. Granulocytes (GRAN), eosinophils (EOS) and neutrophils (NEU) were isolated as in Chouinard et al. (2013). PBMCs were obtained from the PBMC layer and taken as is or otherwise processed for monocyte (MONO), B and T lymphocytes (LYMP) isolation using the EasySep™ monocyte isolation kit, CD19 positive Selection Kit II and CD3 positive selection Kit II respectively, as per the manufacturer’s protocol. Purity of the different isolated leukocytes was always >97% with the exception of B Lymphocytes (90%) with MONO being the main contaminant. Hypothalamus (HYPO) samples were obtained from the Douglas-Bell Canada Brain Bank (McGill University, Montréal, Canada). mRNA was next isolated from the different preparations with TRIzol as per the manufacturer’s protocol. 500 ng of total RNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA) as recommended. qPCR analyses were finally performed on a CFX Connect Real-Time PCR System, using the following primers (forward - reverse): GAPDH (5′-ACATCGCTCAGACACCATG-3′–5′-TGTAGTTGAGGTCAATGAAGGG-3′) 18S (5′-CGCACGGCCGGTACAGTGAA-3′–5′-GGGAGAGGAGCGAGCGACCA-3′) CB₁ (5′-TTCCCTCTTGTGAAGGCACTG-3′–5′-TCTTGACCGTGCTCTTGATGC-3′) and CB₂ (5′-CAAGGCTGTCTTCCTGCTGA-3′–5′-CGGGTGAGCAGAGCTTTGTA-3′). Data represent the mean (±SEM) of 4–6 donors and was obtained using the CFX Maestro Software (Bio-Rad).

Factors Influencing CB₂ Receptor Expression in Human Leukocytes

Some factors were documented as influencing CB₂ receptor expression in human leukocytes. CB₂ expression can increase during inflammation as it is the case in eosinophils from symptomatic allergic donors compared to healthy controls (Frei et al., 2016; Larose et al., 2017), in monocytes of patients after ischemic stroke (Greco et al., 2021), in myeloid and plasmacytoid dendritic cells of patients with multiple sclerosis (Chiurchiu et al., 2013; Sanchez Lopez et al., 2015) and in T lymphocytes of Non-Hodgkin’s lymphomas (Rayman et al., 2007; Robinson et al., 2013). On the other hand, LPS decreased CB₂ receptor expression in isolated dendritic cells and B lymphocytes (Lee et al., 2001; Do et al., 2004). Finally, the CB₂ receptor was not detected in resting macrophages, was present at high levels in responsive and primed cells and was greatly diminished in fully activated cells (Cabral 2010). The latter observation suggests that the CB₂ receptor might have a time-specific function in macrophages during inflammation.

Numerous CB₂ receptor antibodies have been developed but most (if not all) are failing to provide reliable signals in different applications (immunohistochemistry, cytofluorometry and immunoblot), while not always having been characterized with the appropriate controls (control peptide blockade, CB₂ receptor-devoid cells, cross reactivity). Thus, until a clear consensus is achieved on which antibodies are sufficiently reliable, data on CB₂ protein should be interpreted with caution. With that in mind, the CB₂ receptor protein localization can vary. Indeed, Castaneda et al. reported that the CB₂ receptor protein was found intracellularly in most leukocytes with only B lymphocytes expressing it at the extracellular membrane (Castaneda et al., 2013). CB₂-positive B lymphocytes were mainly located in the mantle of secondary lymphoid follicles, which contain immature B lymphocytes while some positive cells also appeared in the germinal centers of secondary follicles, which contain mature B lymphocytes, suggesting an heterogeneous distribution of the receptor during B lymphocytes maturation stages (Galiegue et al., 1995). Immunohistochemical analysis using an N-terminal specific anti-CB₂ antibody revealed high protein expression in the germinal centers of secondary follicles while a C-terminal specific anti-CB₂ antibody (only recognizing a non-phosphorylated inactive receptor) showed positivity primary follicle, the mantle and marginal zones of the secondary follicles where resting cells reside (Rayman et al., 2004). Therefore, active CB₂ seems mainly present on B lymphocytes in the germinal centers.

Impact of CB₂ Receptor Activation in Human Leukocytes

The early studies investigating the roles of the CB₂ receptor, notably those involving cnr2-deficient mice, led to the idea that it is mainly anti-inflammatory (Turcotte et al., 2016). However, recent studies are emerging and indicate that the outcome of CB₂ receptor signaling may differ depending on the experimental model/disease. A good example is experimental asthma. Indeed, early work indicated that the CB₂ receptor agonist WIN 55,212-2 inhibited ovalbumin-induced plasma extravasation in guinea pig airways (Fukuda et al., 2010). In contrast, the CB₂ receptor agonist JWH-133 aggravated ovalbumin-induced asthma in mice while having no effect in dinitrofluorobenzene-induced asthma (Bozkurt et al., 2016; Frei et al., 2016). When house dust mites were utilized as allergen, cnr2-deficient mice were resistant to allergic responses (Ferrini et al., 2017) while an innate lymphoid cell-2 dependent model involving IL-25, IL-33 and/or Alternaria alternate had lower symptoms, decreased eosinophil number, and airway resistance (Hurrell et al., 2021). In humans, CB₂ receptor expression was increased in nasal polyps of aspirin-exacerbated disease patients (Corrado et al., 2018) while being decreased in epithelial cells of asthmatic patients (Fantauzzi et al., 2020).

While we address some leukocytes individually below, the overall impact of CB₂ receptor activation on human leukocytes is summarized in Table 1. However, we underscore that the selectivity of the pharmacological tools targeting CB₂ receptors (agonists, antagonists, inverse agonists) has been often questioned, as exemplified by the work of Soethoudt et al. (2017).

TABLE 1CB₂-mediated effects on human leukocytes and related human cell lines.

Leukocytes or cell lines	Agonist		Antagonist or inverse agonist	Effects	Impact on signaling	References
Eosinophils
Blood	2-AG	1 μM (4 h)	SR144528 (1 μM)	Induce migration in presence of 1 μM NDGA (lipoxygenase inhibitor)		Oka et al. (2004)
		1 μM (1 h)	SR144528 (1 μM)	2-AG-induced migration in presence of 1 μM NDGA is attributed to chemotaxis rather than chemokinesis		Kishimoto et al. (2006)
		3 μM (2 h)	SR144528 (10 μM)	Induce migration in presence of IL-5	Inhibited by the Lyn inhibitor PP2	Larose et al. (2014)
		3 μM (2 h)	AM630 (10 μM)	Induce migration in presence of IL-5	Inhibited by the Lyn inhibitor PP2	Larose et al. (2014)
		250 nM (5 h)	SR144528 (1 μM)	↑ CCL24-induced shape change and migration		Frei et al. (2016)
	CP 55,940	1 μM (2 h)	-	No effect on migration		Larose et al. (2014)
	JWH-133	100–250 nM (5 h)	SR144528 (1 μM)	Induce migration	Migration inhibited by MEK1 inhibitors (U-0126, PD98,059) and the ROCK inhibitor Y-27632	Frei et al. (2016)
				↑ CCL24-induced shape change and migration	Not inhibited by pertussis toxin (PTX; Gα_i-independant), p38 or PI3K inhibitors
				↑ CCL24-induced CD11b upregulation	- ↑ Ca²⁺ influx
				↑ Adhesion to ICAM-1	- Ca²⁺ influx inhibited by the PLC inhibitor U-73122 and the IP3 receptor antagonist 2-APB
Leukemia EoL-1 cells	2-AG	1 μM (4 h)	SR144528 (1 μM)	Induce migration in presence of 1 μM NDGA	Inhibited by PTX (G_i/0-dependant)	Oka et al. (2004)
Leukemia EoL-1 cells	S-777469	100–500 nM (4 h)	-	↓ 2-AG-induced migration		Haruna et al. (2017)
B lymphocytes
Blood	CP 55,940	1–100 nM (72 h)	SR144528 (100–300 nM)	↑ Proliferation		Carayon et al. (1998)
Tonsillar	CP 55,940	1–100 nM (72 h)	SR144528 (100–300 nM)	↑ Proliferation of both naïve and germinal centrosome B lymphocytes		Carayon et al. (1998)
Tonsillar	WIN 55,212–2	10 μM (4 h)	SR144528 (10 nM)	No effect		Gustafsson et al. (2006)
Raji cell line	2-AG	300 nM (4 h)	SR144528 (100 nM)	Induce moderate migration		Rayman et al. (2004)
Raji cell line	2-AG	300 nM (4 h)	SR144528 (100 nM)	↑ Migration following stimulation with an anti-sCD40 antibody		Rayman et al. (2004)
Rec-1 cell line	WIN 55,212–2	10 μM (4 h)	SR144528 (10 nM)	↑ Apoptosis (caspase-3 activity)	- Inhibited by the CB₁ inverse agonist SR141716A and by p38 inhibitors	Gustafsson et al. (2006)
Rec-1 cell line	WIN 55,212–2	10 μM (4 h)	SR144528 (10 nM)	↑ Ceramide levels (downstream of p38 activation)	- Not inhibited by c-Jun or MEK-1 inhibitors	Gustafsson et al. (2006)
SKW 6.4 cell line	-		SR144528 (5–10 μM)	↓ IL-6 induced secretion of soluble IgM	- Inhibited by the CB₂ agonist HU308	Feng et al. (2014)
			AM630 (5 μM)	- ↓ IL-6-induced p-STAT3	- Do not degrade IκBα as the NF-κB inhibitor Bay11-7085
				- ↑ Pax5 (first) and Bcl-6 mRNA levels
Neutrophils
Blood	2-AG	1 μM (4 h)	SR144528 (1 μM)	No effect on migration in presence of NDGA		Oka et al. (2004)
	2-AG	300 nM (20 min)	SR144528 (1 μM)	No motility or morphologic alterations		Kurihara et al. (2006)
	JWH-015	100 nM-10 μM (20 min)	SR144528 (1 μM)	No motility or morphologic alterations		Kurihara et al. (2006)
	JWH-133	1 μM (2 h)	-	No effect on neutrophil function		Zhou et al. (2020)
		100 nM (5 h)	SR144528 (1 μM)	No effect on IL-8-induced migration		Frei et al. (2016)
		100 nM-1 μM (30 min)	AM630 (500 nM)	↓ LPS-induced VEGF-A		Braile et al. (2021)
		100 nM-1 μM (30 min)	AM630 (500 nM)	↓ LPS-induced endothelial permeability		Braile et al. (2021)
T lymphocytes
Blood	AEA	0.5–5 μM (6 h)	SR144528 (1 μM)	↓ Proliferation		Cencioni et al. (2010)
				↓ IL-2, TNF-α and IFN-γ
				↓ IL-17
	JWH-015	20 μM (1 h)	AM630 (500 nM)	↓ CXCL12-induced chemotaxis		Ghosh et al. (2006)
		250 nM (2 h)	AM630 (500 nM)	↓ Proliferation	↓ p-ERK1/2	Borner et al. (2009)
		250 nM (2 h)	AM630 (500 nM)	↓ IL-2	↓ p-ERK1/2	Borner et al. (2009)
		1 μM (6 h)	SR144528 (1 μM)	↓ Proliferation		Cencioni et al. (2010)
				↓ IL-2, TNF-α and IFN-γ
				↓ IL-17
		1 μM (1–30 min)	AM630 (1 μM)	↓ HIV-1 infection in primary CD4 T cells		Costantino et al. (2012)
	JWH-133	0.001–10 μM (30 min)	-	↓ CXCL12-induced chemotaxis	↑ p-ERK1/2	Coopman et al. (2007)
		100 nM-1 μM (1–30 min)	AM630 (1 μM)	↓ HIV-1 infection in primary CD4 T cells	↓ p-ERK1/2 and p-Akt	Costantino et al. (2012)
				↓ Activation of CXCR4 by SDF-1α
				↓ Levels of F-actin
	Δ⁹-THC	5 μg/ml (18 h)	SR144528 (1 μM)	↓ Percentage of T lymphocytes expressing IFN-γ		Yuan et al. (2002)
				↓ IFN-γ intracellular level detected per cell
				↑ IL-4 and IL-5
Jurkat cells	GW 405833	10–40 μM (3–24 h)	AM630 (1 μg/ml)	↓ Cell viability		Huang et al. (2019)
	GW 405833	10–40 μM (3–24 h)	AM630 (1 μg/ml)	↑ Cell apoptosis (annexin V)		Huang et al. (2019)
	JWH-015	20 μM (1 h)	AM630 (500 nM)	↓ CXCL12-induced chemotaxis	↑ CXCL12-induced p-ERK1/2	Ghosh et al. (2006)
				↓ Transendothelial migration	Migration not inhibited by the MEK-1 inhibitor PD 98,059
				↓ PMA-induced MMP9
		250 nM (2 h)	AM630 (500 nM)	↓ anti-CD3/anti-CD28-induced IL-2 production	- ↓ p-ERK1/2	Borner et al. (2009)
					- ↑ p-Lck
					- ↓ cAMP levels
					- Increased cAMP levels were inhibited by PTX
	LV50	10 μM (4–72 h)	SR144528 (1 μM)	↓ T cell proliferation		Capozzi et al. (2018)
	LV50	10 μM (4–72 h)	SR144528 (1 μM)	↑ Apoptosis		Capozzi et al. (2018)
	Δ⁹-THC	1–5 μM (1–2 h)	SR144528 (2 μM)	↓ Cell viability		Herrera et al. (2006)
				↑ Apoptosis (Annexin 5)
				↑ Ceramide levels
				Activation of caspase 8 at a post-mitochondrial level
Monocytes
Blood	2-AG	10 nM–10 μM (4 h)	SR144528 (1 μM)	↑ Migration (chemotaxis toward 2-AG)		Kishimoto et al. (2003)
	(E)-β-caryophyllene	500 nM (18 h)	AM630 (5 μM)	↓ LPS-induced IL-1β and TNFα	↓ LPS-induced p-ERK1/2 and p-JNK1/2	Gertsch et al. (2008)
	JWH-015	5–20 μM (60 min)	SR144528 (1 μM)	↓ CCL2- and CCL3-induced migration	- Inhibited by PI3K and the MEK-1 inhibitors	Montecucco et al. (2008)
				↓ CCR2 and CCR1 mRNA expression	- Not inhibited by the p38 inhibitor SB-203580
				↓ IFNγ-induced ICAM-1 induction
		1–10 μM (20 min)	-	↓ IL-1β		Rizzo et al. (2019)
	JWH-133	1 μM (18 h)	SR144528 (1 μM)	-	↑ p-ERK1/2	Gertsch et al. (2008)
	JWH-133	0.1–10 μM (days 4, 7 and 10)	-	↓ HIV-1 viral infection during differentiation in monocyte derived macrophages		Williams et al. (2014)
U937 cells	2-AG	1 μM (5 min)	SR144528 (3 μM)	↑ Adhesion to fibronectin		Gokoh et al. (2005a)
	CP 55,940	1 nM–1 μM (2 h)	SR144528 (1 μM)	↓ HIV-1 transactivating protein-enhanced adhesion of cells to extracellular matrix protein, such as collagen IV and laminin		Raborn et al. (2014)
	WIN 55,212–2	1–10 μM (2 h)	AM630 (1 μM)	↓ Adhesion to HUVECs		Zhao et al. (2010)
Mast cells
Endometrial	JWH-015	10⁻⁸–10⁻⁶ M (2 h)	-	↓ Calcium ionophore A23187-induced degranulation		Iuvone et al. (2008)
Macrophages
Monocyte-derived macrophages (healthy subjects)	JWH-015	50 nM (30 min)	SR144528 (50 nM–0.1 μM)	↓ oxLDL-induced CD36		Chiurchiu et al. (2014)
	JWH-015	50 nM (30 min)	SR144528 (50 nM–0.1 μM)	↓ oxLDL-induced TNF-α, IL-12 and IL-10		Chiurchiu et al. (2014)
	Lenabasum	0.1–30 μM (Day 0, 3, and 6)	-	No effect		Tarique et al. (2020)
Monocyte-derived macrophages (patients with cystic fibrosis)	Lenabasum	0.1–30 μM (Day 0, 3, and 6)	-	↓ Macrophage polarization into pro-inflammatory M1 phenotype		Tarique et al. (2020)
	Lenabasum	0.1–30 μM (Day 0, 3, and 6)	-	↓ IL-8 and TNF-α secretion		Tarique et al. (2020)
Lung	JWH-133	1 μM (10 min)	AM630 (0.5 μM)	↓ LPS-induced VEGF-A and VEGF-C	↑ p-ERK1/2	Staiano et al. (2016)
Lung	JWH-133	1 μM (10 min)	AM630 (0.5 μM)	↓ LPS-induced IL-6	↑ p-ERK1/2	Staiano et al. (2016)
HL-60-derived macrophage	2-AG	1 μM (1 min)	SR144528 (1 μM)	Induce morphological changes such as the extension of pseudopods	- Inhibited by PTX (G_i/0-dependant)	Gokoh et al. (2005b)
				↑ Actin polymerization	- Inhibited by selective chelating agent for intracellular free Ca²⁺ BAPTA-AM
					- Inhibited by the PI3K inhibitor wortmannin -Not inhibited by the tyrosine kinase inhibitor herbimycin, the MEK-1 inhibitor PD 98,059 or the PKC inhibitor Ro-31–8220
THP-1-derived macrophage M2	JWH-015	1–5 μM (12 h)	-	↓ Migration of A549 cells	↓ p-ERK1/2 and p-STAT3	Ravi et al. (2016)
Dendritic cells
Myeloid	AEA	2.5 μM (4 h)	SR144528 (1 μM)	↓ R848-induced TNF-α, IL-12p40, IL-6		Chiurchiu et al. (2013)
Myeloid	JWH-015	1 μM (4 h)	SR144528 (1 μM)	↓ R848-induced TNF-α, IL-12p40, IL-6		Chiurchiu et al. (2013)
Plasmacytoid (healthy subjects)	AEA	2.5 μM (4 h)	SR144528 (1 μM)	↓ R848-induced TNF-α, IFN-α		Chiurchiu et al. (2013)
	2-AG	10 μM (18 h)	SR144528 (1 μM)	↓ CpGA-induced IFNα		Rahaman et al. (2019)
	2-AG	10 μM (18 h)	SR144528 (1 μM)	↓ TLR9 activation		Rahaman et al. (2019)
	JWH-015	1 μM (4 h)	SR144528 (1 μM)	↓ R848-induced TNF-α and IFN-α		Chiurchiu et al. (2013)
	JWH-015	0.01–1 μM (5 h)	-	↓ CpG-induced IFNα and TNFα	↓ p-IRF7, p-TBK1, p-NF-κB and p-IKKγ	Henriquez et al. (2019)
	JWH-133	0.001–0.1 μM (5 h)	-	↓ CpG-induced IFNα and TNFα	↓ p-IRF7, p-TBK1, p-NF-κB and p-IKKγ	Henriquez et al. (2019)
Plasmacytoid (patient with multiple sclerosis)	AEA	2.5 μM (4 h)	SR144528 (1 μM)	No effect		Chiurchiu et al. (2013)
Plasmacytoid (patient with multiple sclerosis)	JWH-015	1 μM (4 h)	SR144528 (1 μM)	No effect		Chiurchiu et al. (2013)

Human Eosinophils

Eosinophils participate in innate immunity against parasites and in the development/persistence of diverse inflammatory responses, notably allergies and asthma. Studies involving human eosinophils and CB receptors are scarce. Their treatment with either the endocannabinoid 2-AG and/or CB₂ receptor agonists stimulated their migration or potentiated their migration toward other chemoattractants (Oka et al., 2004; Kishimoto et al., 2006; Larose et al., 2014; Frei et al., 2016). Importantly, these effects were prevented by the CB₂ receptor antagonists AM630 and/or SR144528. Consistent with a CB₂-mediated increased in eosinophil migration, cannabis use has been linked to some cases of acute eosinophilic pneumonia, although no demonstration has proven that this involved the CB₂ receptor (Sauvaget et al., 2010; Liebling and Siu 2013; Natarajan et al., 2013; Ocal et al., 2016; Mull et al., 2020). Interestingly, while JWH-133 led to a moderate chemotactic response in human eosinophils, it had no effect on mouse eosinophils (Frei et al., 2016). Altogether, the current data support that the CB₂ receptor stimulates eosinophil migration. This could eventually lead to increased parasitic defenses but also to a worsening of eosinophils-related inflammatory diseases.

Human B Lymphocytes

B lymphocytes maturation and differentiation are complex processes. Following their activation, naïve cells (spleen marginal zone) proliferate and differentiate into short-lived plasma cells, while cells from the follicles undergo massive proliferation and form germinal centers, where long-lived plasma and memory cells are formed (Basu et al., 2013). Very little is known about the role of the CB₂ receptor in human B lymphocytes but their treatment with CP 55,940 increased their proliferation, a phenomenon blocked by SR144528 (Carayon et al., 1998). In mice, activation of the CB₂ receptor has been associated with B lymphocyte differentiation, migration, proliferation and antibody class switching (Jorda et al., 2002; Tanikawa et al., 2007; Agudelo et al., 2008), suggesting the receptor is part of the B lymphocytes immune programing, playing an important role in B lymphocyte repertoire formation (Pereira et al., 2009).

Human Neutrophils

Neutrophils are first responders of the innate immune system, playing crucial roles in acute inflammatory responses and host defense. They employ several strategies to fight microbes, including the phagocytosis and killing of pathogens with the help of their granule content. Studies showing a CB₂-receptor-mediated effect of human neutrophils were not conclusive and contaminating eosinophils in neutrophil preparations might have caused a red herring situation, eosinophils being responsible for most of the CB₂ receptor signal/effects (Figure 1 and Expression of the CB ₁ and CB ₂ Receptors by Human Blood Leukocytes). In fact, numerous studies indicated that endocannabinoids as well as selective and non-selective CB₂ receptor agonists do not diminish human neutrophil functions (migration, superoxide generation and degranulation) via the CB₂ receptor and when they display an inhibitory effect on their functional responses it is mostly related to a mechanism distinct from the CB₁ and CB₂ receptors (Deusch et al., 2003; Kraft et al., 2004; Oka et al., 2004; McHugh et al., 2008; Chouinard et al., 2011; Montecucco et al., 2012; Zhou et al., 2020), which is consistent with their lack/very low expression of the CB₂ receptor. In contrast, JWH-133 inhibited the release of VEGF-A but not CXCL8 from LPS-stimulated human neutrophils, a phenomenon prevented by the CB₂ receptor antagonist AM630 (Braile et al., 2021).

• In vivo studies indicated that mouse neutrophils are more responsive to CB₂ receptor activation than human neutrophils. As such, Cnr2 ^−/− mice models reported increased neutrophil numbers at inflammatory sites (Alferink et al., 2016; Kapellos et al., 2017; Kapellos et al., 2019). Accordingly, CB₂ activation by selective agonists suppressed neutrophil recruitment to the inflammation site (Horvath et al., 2012; Andrade-Silva et al., 2016; Wang et al., 2016; Parlar et al., 2018; Kapellos et al., 2019). However, it is not clear whether the reported evidence is a matter of mouse neutrophil responsiveness or of indirect CB₂-dependent effects mediated by other cells (Kraft and Kress 2005). At this point, we cannot exclude that a CB₂-dependent mechanism prevents neutrophil recruitment into by impairing their transmigration into the tissues and by affecting other cells (e.g., endothelial cells) as proposed earlier (Nilsson et al., 2006).

Human T Lymphocytes

Cytotoxic CD8 T lymphocytes are responsible for the elimination of invading/dysfunctional cells while CD4 T lymphocytes produce a myriad of inflammatory mediators and are referred to as helper lymphocytes (Th). Although CB₂ receptor expression was barely detected in circulating T lymphocytes (Figure 1), several studies reported that CB₂ receptor expression is increased in activated T lymphocytes and that its activation decreases their proliferation (Borner et al., 2009; Cencioni et al., 2010; Capozzi et al., 2018). This is accompanied with decreased IL-2 production and increased apoptosis (Herrera et al., 2006; Borner et al., 2009; Cencioni et al., 2010; Capozzi et al., 2018; Huang et al., 2019). Interestingly, CB₂ receptor activation seems to exert divergent effects depending on the T lymphocyte subtype with the tendency to decrease human Th1 and Th17 functions, while promoting those of Th2. For instance, Δ⁹-THC decreased in a CB₂-dependant manner the percentage of human T lymphocytes expressing IFN-γ, and intracellular levels of IFN-γ per cells (Th1), while increasing levels of IL-4 and IL-5 (Th2) (Yuan et al., 2002). Accordingly, a decrease in IL-17 levels was found in JWH-015-treated T lymphocytes (Cencioni et al., 2010). Finally, the CB₂ agonist Lenabasum reduced TNF-α in both CD8 and CD4 T lymphocytes (Th1). The treatment also decreased IL-17 levels (Th17) as well as Th1 and Th17 respective signature transcription factors T-bet and RORγt (Tiberi et al., 2021).

Human Monocytes

Blood monocytes migrate into tissues where they differentiate into macrophages or convert into non-classical monocytes (Guilliams et al., 2018). 2-AG is a CB₂-dependant human monocyte chemoattractant (Kishimoto et al., 2003) and induces the adhesion of human monocytic U937 cells to fibronectin (Gokoh et al., 2005a). However, JWH-015 decreased the CCL2-and CCL3-induced migration of human monocytes by decreasing their receptors’ expression (Montecucco et al., 2008). JWH-015 also reduces human monocyte differentiation and U937 cells adhesion to extracellular matrix proteins, both induced by HIV-1 (Raborn et al., 2014; Williams et al., 2014). Finally, CB₂ receptor engagement in human monocytes was shown to decrease the LPS-induced IL-1β and IL-6 production (Gu et al., 2019; Rizzo et al., 2019).

Human Macrophages

Macrophages are resident cells that are remarkably versatile, exerting important roles in development, homeostasis, tissue repair and immunity. The endocannabinoid 2-AG was found to induce shape changes of HL-60-derived macrophages in a CB₂-depandent manner (Gokoh et al., 2005b). Additionally, CB₂ receptor activation with JWH-015 or JWH-133 decreased the LPS-induced VEGF-A, VEGF-C IL-6 release, as well as the oxLDL-induced release of TNF-α, IL-12 and IL-10 (Chiurchiu et al., 2014; Staiano et al., 2016). In mice, the CB₂ receptor was shown to switch the polarization of M1 macrophage into M2 macrophage (Duerr et al., 2014; Denaes et al., 2016; Du et al., 2018). Such a phenomenon has been partially observed in humans by Tarique et al. who showed that Lenabasum decreased the polarization (M1) of monocyte-derived macrophage obtained from cystic fibrosis patients (Tarique et al., 2020).

Human Mast Cells

Mast cells are strategically located at the interface with the external environment, acting as key initiators of local inflammatory responses (Elieh Ali Komi et al., 2020). The first evidence that they could be regulated by the CB₂ receptor came from the rat basophilic leukemia cell line (RBL-2H3) expressing the CB₂ receptor (Facci et al., 1995). However, while the authors showed that N-palmitoyl-ethanolamine (PEA) inhibited serotonin release AEA did not. However, PEA interacts with PPARα (Lo Verme et al., 2005) and its initial effects are likely linked to PPARα. In humans, the treatment of isolated mast cells with JWH-015 decreased their degranulation in vitro (Iuvone et al., 2008).

Human Dendritic Cells

Dendritic cells are sentinels of the immune system bridging the innate and adaptive immunity by ingesting pathogens and transporting antigens to lymphoid tissues. Stimulation of CB₂ receptor with CB₂ receptor agonists reduced their cytokine production. Indeed, AEA and JWH-015 decreased R848-induced levels of TNF-α, IL-12p40 and IL-6 by myeloid dendritic cells while AEA, 2-AG, JWH-015 and JWH-133 decreased levels of R848-and/or CpG-induced IFN-α by plasmacytoid dendritic cells by a mechanisms involving NF-κB and IKKγ signalization (Chiurchiu et al., 2013; Henriquez et al., 2019; Rahaman et al., 2019).

Conclusion

It is becoming clear that the CB₂ receptor plays important roles in the regulation of several inflammatory processes. However, while the first studies investigating the role of this receptor in mice led to the concept that its function was mainly anti-inflammatory, new evidence is challenging this concept, notably in allergic diseases, which usually involve cells such as eosinophils and B lymphocytes, whose functional responses to CB₂ receptor activation simulates them, in human-based studies. Moreover, the scarcity of human studies investigating the CB₂ receptor makes our understanding of the latter difficult at this point and underscores the urgency of performing additional work involving human samples/cells to deepen our understanding of CB₂-receptor-driven inflammatory responses and establish to what extent we can translate findings from experimental models to the clinic. It is thus urgent to further characterize the functions of the CB₂ receptor in human leukocytes and inflammatory diseases.

Acknowledgments

We would like to thank Andréanne Côté and Annie Roy for providing the blood samples.

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Ethics Statement

The studies involving human participants were reviewed and approved by the Comité d’éthique de la recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec. The participants provided their written informed consent to participate in this study.

Author Contributions

Conceptualization: MS, VR, VD, and NF; Investigation: MS and VR; Data curation—formal analysis: MS, VR, and NF; Writing—original draft: MS and NF; Writing—review, editing, and revision: MS, VR, VD, and NF.

Funding

This work was supported by grants to NF from The Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03777) and to VD from the Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health. VR was supported by a post-doctoral award from the Québec Heart and Lung Institute Foundation.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Untitled section

References

Agudelo M., Newton C., Widen R., Sherwood T., Nong L., Friedman H., et al. (2008). Cannabinoid Receptor 2 (CB2) Mediates Immunoglobulin Class Switching from IgM to IgE in Cultures of Murine-Purified B Lymphocytes. J. Neuroimmune Pharmacol. 3 (1), 35–42. 10.1007/s11481-007-9088-9
Alferink J., Specht S., Arends H., Schumak B., Schmidt K., Ruland C., et al. (2016). Cannabinoid Receptor 2 Modulates Susceptibility to Experimental Cerebral Malaria through a CCL17-dependent Mechanism. J. Biol. Chem. 291 (37), 19517–19531. 10.1074/jbc.M116.746594
Andrade-Silva M., Correa L. B., Candéa A. L., Cavalher-Machado S. C., Barbosa H. S., Rosas E. C., et al. (2016). The Cannabinoid 2 Receptor Agonist β-caryophyllene Modulates the Inflammatory Reaction Induced by Mycobacterium Bovis BCG by Inhibiting Neutrophil Migration. Inflamm. Res. 65 (11), 869–879. 10.1007/s00011-016-0969-3
Basu S., Ray A., Dittel B. N. (2013). Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens. PLoS One 8 (6), e67587. 10.1371/journal.pone.0067587
Börner C., Smida M., Höllt V., Schraven B., Kraus J. (2009). Cannabinoid Receptor Type 1- and 2-mediated Increase in Cyclic AMP Inhibits T Cell Receptor-Triggered Signaling. J. Biol. Chem. 284 (51), 35450–35460. 10.1074/jbc.M109.006338
Bozkurt T. E., Kaya Y., Durlu-Kandilci N. T., Onder S., Sahin-Erdemli I. (2016). The Effect of Cannabinoids on Dinitrofluorobenzene-Induced Experimental Asthma in Mice. Respir. Physiol. Neurobiol. 231, 7–13. 10.1016/j.resp.2016.05.012
Braile M., Cristinziano L., Marcella S., Varricchi G., Marone G., Modestino L., et al. (2021). LPS-mediated Neutrophil VEGF-A Release Is Modulated by Cannabinoid Receptor Activation. J. Leukoc. Biol. 109 (3), 621–631. 10.1002/JLB.3A0520-187R
Brown S. M., Wager-Miller J., Mackie K. (2002). Cloning and Molecular Characterization of the Rat CB2 Cannabinoid Receptor. Biochim. Biophys. Acta 1576 (3), 255–264. 10.1016/s0167-4781(02)00341-x
Cakir M., Tekin S., Doganyigit Z., Cakan P., Kaymak E. (2019). The Protective Effect of Cannabinoid Type 2 Receptor Activation on Renal Ischemia-Reperfusion Injury. Mol. Cel Biochem 462 (1-2), 123–132.
Capozzi A., Mattei V., Martellucci S., Manganelli V., Saccomanni G., Garofalo T., et al. (2018). Anti-proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells. Int. J. Mol. Sci. 19 (7), 1958. 10.3390/ijms19071958
Carayon P., Marchand J., Dussossoy D., Derocq J. M., Jbilo O., Bord A., et al. (1998). Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors during B-Cell Differentiation. Blood 92 (10), 3605–3615. 10.1182/blood.v92.10.3605.422k05_3605_3615
Castaneda J. T., Harui A., Kiertscher S. M., Roth J. D., Roth M. D. (2013). Differential Expression of Intracellular and Extracellular CB(2) Cannabinoid Receptor Protein by Human Peripheral Blood Leukocytes. J. Neuroimmune Pharmacol. 8 (1), 323–332. 10.1007/s11481-012-9430-8
Cencioni M. T., Chiurchiù V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., et al. (2010). Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors. PLoS One 5 (1), e8688. 10.1371/journal.pone.0008688
Chiurchiù V., Cencioni M. T., Bisicchia E., De Bardi M., Gasperini C., Borsellino G., et al. (2013). Distinct Modulation of Human Myeloid and Plasmacytoid Dendritic Cells by Anandamide in Multiple Sclerosis. Ann. Neurol. 73 (5), 626–636. 10.1002/ana.23875
Chiurchiù V., Lanuti M., Catanzaro G., Fezza F., Rapino C., Maccarrone M. (2014). Detailed Characterization of the Endocannabinoid System in Human Macrophages and Foam Cells, and Anti-inflammatory Role of Type-2 Cannabinoid Receptor. Atherosclerosis 233 (1), 55–63. 10.1016/j.atherosclerosis.2013.12.042
Chouinard F., Lefebvre J. S., Navarro P., Bouchard L., Ferland C., Lalancette-Hébert M., et al. (2011). The Endocannabinoid 2-Arachidonoyl-Glycerol Activates Human Neutrophils: Critical Role of its Hydrolysis and de novo Leukotriene B4 Biosynthesis. J. Immunol. 186 (5), 3188–3196. 10.4049/jimmunol.1002853
Chouinard F., Turcotte C., Guan X., Larose M. C., Poirier S., Bouchard L., et al. (2013). 2-Arachidonoyl-glycerol- and Arachidonic Acid-Stimulated Neutrophils Release Antimicrobial Effectors against E. coli, S. aureus, HSV-1, and RSV. J. Leukoc. Biol. 93 (2), 267–276. 10.1189/jlb.0412200
Coopman K., Smith L. D., Wright K. L., Ward S. G. (2007). Temporal Variation in CB2R Levels Following T Lymphocyte Activation: Evidence that Cannabinoids Modulate CXCL12-Induced Chemotaxis. Int. Immunopharmacol 7 (3), 360–371. 10.1016/j.intimp.2006.11.008
Corrado A., Battle M., Wise S. K., Lee F. E., Guidot D. M., DelGaudio J. M., et al. (2018). Endocannabinoid Receptor CB2R Is Significantly Expressed in Aspirin-Exacerbated Respiratory Disease: a Pilot Study. Int. Forum Allergy Rhinol 8 (10), 1184–1189. 10.1002/alr.22163
Costantino C. M., Gupta A., Yewdall A. W., Dale B. M., Devi L. A., Chen B. K. (2012). Cannabinoid Receptor 2-mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells. PLoS One 7 (3), e33961. 10.1371/journal.pone.0033961
Denaës T., Lodder J., Chobert M. N., Ruiz I., Pawlotsky J. M., Lotersztajn S., et al. (2016). The Cannabinoid Receptor 2 Protects against Alcoholic Liver Disease via a Macrophage Autophagy-dependent Pathway. Sci. Rep. 6, 28806. 10.1038/srep28806
Deusch E., Kraft B., Nahlik G., Weigl L., Hohenegger M., Kress H. G. (2003). No Evidence for Direct Modulatory Effects of delta 9-tetrahydrocannabinol on Human Polymorphonuclear Leukocytes. J. Neuroimmunol 141 (1-2), 99–103. 10.1016/s0165-5728(03)00259-5
Devane W. A., Dysarz F. A., 3rd, Johnson M. R., Melvin L. S., Howlett A. C. (1988). Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol. Pharmacol. 34 (5), 605–613.
Di Marzo V., Melck D., Bisogno T., De Petrocellis L. (1998). Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action. Trends Neurosci. 21 (12), 521–528. 10.1016/s0166-2236(98)01283-1
Di Marzo V. (2018). New Approaches and Challenges to Targeting the Endocannabinoid System. Nat. Rev. Drug Discov. 17 (9), 623–639. 10.1038/nrd.2018.115
Do Y., McKallip R. J., Nagarkatti M., Nagarkatti P. S. (2004). Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-kappaB-dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation. J. Immunol. 173 (4), 2373–2382. 10.4049/jimmunol.173.4.2373
Dothel G., Chang L., Shih W., Barbaro M. R., Cremon C., Stanghellini V., et al. (2019). Micro-Opioid Receptor, Beta-Endorphin, and Cannabinoid Receptor-2 Are Increased in the Colonic Mucosa of Irritable Bowel Syndrome Patients. Neurogastroenterol Motil. 31 (11), e13688. 10.1111/nmo.13688
Du Y., Ren P., Wang Q., Jiang S. K., Zhang M., Li J. Y., et al. (2018). Cannabinoid 2 Receptor Attenuates Inflammation during Skin Wound Healing by Inhibiting M1 Macrophages rather Than Activating M2 Macrophages. J. Inflamm. (Lond) 15, 25. 10.1186/s12950-018-0201-z
Duerr G. D., Heinemann J. C., Suchan G., Kolobara E., Wenzel D., Geisen C., et al. (2014). The Endocannabinoid-CB2 Receptor axis Protects the Ischemic Heart at the Early Stage of Cardiomyopathy. Basic Res. Cardiol. 109 (4), 425. 10.1007/s00395-014-0425-x
Elieh Ali Komi D., Wöhrl S. L., Bielory L. (2020). Mast Cell Biology at Molecular Level: a Comprehensive Review. Clin. Rev. Allergy Immunol. 58 (3), 342–365. 10.1007/s12016-019-08769-2
Ellert-Miklaszewska A., Grajkowska W., Gabrusiewicz K., Kaminska B., Konarska L. (2007). Distinctive Pattern of Cannabinoid Receptor Type II (CB2) Expression in Adult and Pediatric Brain Tumors. Brain Res. 1137 (1), 161–169. 10.1016/j.brainres.2006.12.060
Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. (1995). Mast Cells Express a Peripheral Cannabinoid Receptor with Differential Sensitivity to Anandamide and Palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A. 92 (8), 3376–3380. 10.1073/pnas.92.8.3376
Fantauzzi M. F., Aguiar J. A., Tremblay B. J., Mansfield M. J., Yanagihara T., Chandiramohan A., et al. (2020). Expression of Endocannabinoid System Components in Human Airway Epithelial Cells: Impact of Sex and Chronic Respiratory Disease Status. ERJ Open Res. 6 (4). 10.1183/23120541.00128-2020
Feng R., Milcarek C. A., Xie X. Q. (2014). Antagonism of Cannabinoid Receptor 2 Pathway Suppresses IL-6-induced Immunoglobulin IgM Secretion. BMC Pharmacol. Toxicol. 15, 30. 10.1186/2050-6511-15-30
Ferrini M. E., Hong S., Stierle A., Stierle D., Stella N., Roberts K., et al. (2017). CB2 Receptors Regulate Natural Killer Cells that Limit Allergic Airway Inflammation in a Murine Model of Asthma. Allergy 72 (6), 937–947. 10.1111/all.13107
Frei R. B., Luschnig P., Parzmair G. P., Peinhaupt M., Schranz S., Fauland A., et al. (2016). Cannabinoid Receptor 2 Augments Eosinophil Responsiveness and Aggravates Allergen-Induced Pulmonary Inflammation in Mice. Allergy 71 (7), 944–956. 10.1111/all.12858
Freundt-Revilla J., Heinrich F., Zoerner A., Gesell F., Beyerbach M., Shamir M., et al. (2018). The Endocannabinoid System in Canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis. PLoS One 13 (2), e0187197. 10.1371/journal.pone.0187197
Fukuda H., Abe T., Yoshihara S. (2010). The Cannabinoid Receptor Agonist WIN 55,212-2 Inhibits Antigen-Induced Plasma Extravasation in guinea Pig Airways. Int. Arch. Allergy Immunol. 152 (3), 295–300. 10.1159/000283042
Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., et al. (1995). Expression of central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur. J. Biochem. 232 (1), 54–61. 10.1111/j.1432-1033.1995.tb20780.x
Gertsch J., Leonti M., Raduner S., Racz I., Chen J. Z., Xie X. Q., et al. (2008). Beta-caryophyllene Is a Dietary Cannabinoid. Proc. Natl. Acad. Sci. U S A. 105 (26), 9099–9104. 10.1073/pnas.0803601105
Ghosh S., Preet A., Groopman J. E., Ganju R. K. (2006). Cannabinoid Receptor CB2 Modulates the CXCL12/CXCR4-Mediated Chemotaxis of T Lymphocytes. Mol. Immunol. 43 (14), 2169–2179. 10.1016/j.molimm.2006.01.005
Gokoh M., Kishimoto S., Oka S., Metani Y., Sugiura T. (2005a). 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Enhances the Adhesion of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes. FEBS Lett. 579 (28), 6473–6478. 10.1016/j.febslet.2005.10.030
Gokoh M., Kishimoto S., Oka S., Mori M., Waku K., Ishima Y., et al. (2005b). 2-arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces Rapid Actin Polymerization in HL-60 Cells Differentiated into Macrophage-like Cells. Biochem. J. 386 (Pt 3), 583–589. 10.1042/BJ20041163
Graham E. S., Angel C. E., Schwarcz L. E., Dunbar P. R., Glass M. (2010). Detailed Characterisation of CB2 Receptor Protein Expression in Peripheral Blood Immune Cells from Healthy Human Volunteers Using Flow Cytometry. Int. J. Immunopathol Pharmacol. 23 (1), 25–34. 10.1177/039463201002300103
Greco R., Demartini C., Zanaboni A., Tumelero E., Elisa C., Persico A., et al. (2021). Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. Transl Stroke Res. 12 (4), 550–558. 10.1007/s12975-020-00851-8
Gu Z., Singh S., Niyogi R. G., Lamont G. J., Wang H., Lamont R. J., et al. (2019). Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens. Front. Immunol. 10, 2288. 10.3389/fimmu.2019.02288
Guilliams M., Mildner A., Yona S. (2018). Developmental and Functional Heterogeneity of Monocytes. Immunity 49 (4), 595–613. 10.1016/j.immuni.2018.10.005
Gustafsson K., Christensson B., Sander B., Flygare J. (2006). Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and P38 Activation in Mantle Cell Lymphoma. Mol. Pharmacol. 70 (5), 1612–1620. 10.1124/mol.106.025981
Haruna T., Soga M., Morioka Y., Imura K., Furue Y., Yamamoto M., et al. (2017). The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice. Pharmacology 99 (5-6), 259–267. 10.1159/000455916
Henriquez J. E., Crawford R. B., Kaminski N. E. (2019). Suppression of CpG-ODN-Mediated IFNα and TNFα Response in Human Plasmacytoid Dendritic Cells (pDC) by Cannabinoid Receptor 2 (CB2)-specific Agonists. Toxicol. Appl. Pharmacol. 369, 82–89. 10.1016/j.taap.2019.02.013
Herrera B., Carracedo A., Diez-Zaera M., Gómez del Pulgar T., Guzmán M. G., Velasco G. (2006). The CB2 Cannabinoid Receptor Signals Apoptosis via Ceramide-dependent Activation of the Mitochondrial Intrinsic Pathway. Exp. Cel Res 312 (11), 2121–2131. 10.1016/j.yexcr.2006.03.009
Horváth B., Magid L., Mukhopadhyay P., Bátkai S., Rajesh M., Park O., et al. (2012). A New Cannabinoid CB2 Receptor Agonist HU-910 Attenuates Oxidative Stress, Inflammation and Cell Death Associated with Hepatic Ischaemia/reperfusion Injury. Br. J. Pharmacol. 165 (8), 2462–2478. 10.1111/j.1476-5381.2011.01381.x
Howlett A. C., Abood M. E. (2017). CB1 and CB2 Receptor Pharmacology. Adv. Pharmacol. 80, 169–206. 10.1016/bs.apha.2017.03.007
Huang Z. B., Zheng Y. X., Li N., Cai S. L., Huang Y., Wang J., et al. (2019). Protective Effects of Specific Cannabinoid Receptor 2 Agonist GW405833 on Concanavalin A-Induced Acute Liver Injury in Mice. Acta Pharmacol. Sin 40 (11), 1404–1411. 10.1038/s41401-019-0213-0
Hurrell B. P., Helou D. G., Shafiei-Jahani P., Howard E., Painter J. D., Quach C., et al. (2021). Cannabinoid Receptor II Engagement Promotes ILC2 Expansion and Enhances ILC2-dependent Airway Hyperreactivity. J. Allergy Clin. Immunol..
Iuvone T., De Filippis D., Di Spiezio Sardo A., D'Amico A., Simonetti S., Sparice S., et al. (2008). Selective CB2 Up-Regulation in Women Affected by Endometrial Inflammation. J. Cel Mol Med 12 (2), 661–670. 10.1111/j.1582-4934.2007.00085.x
Jordà M. A., Verbakel S. E., Valk P. J., Vankan-Berkhoudt Y. V., Maccarrone M., Finazzi-Agrò A., et al. (2002). Hematopoietic Cells Expressing the Peripheral Cannabinoid Receptor Migrate in Response to the Endocannabinoid 2-arachidonoylglycerol. Blood 99 (8), 2786–2793. 10.1182/blood.v99.8.2786
Kapellos T. S., Recio C., Greaves D. R., Iqbal A. J. (20172017). Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators Inflamm. 2017, 4315412. 10.1155/2017/4315412
Kapellos T. S., Taylor L., Feuerborn A., Valaris S., Hussain M. T., Rainger G. E., et al. (2019). Cannabinoid Receptor 2 Deficiency Exacerbates Inflammation and Neutrophil Recruitment. FASEB J. 33 (5), 6154–6167. 10.1096/fj.201802524R
Kishimoto S., Gokoh M., Oka S., Muramatsu M., Kajiwara T., Waku K., et al. (2003). 2-arachidonoylglycerol Induces the Migration of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes through the Cannabinoid CB2 Receptor-dependent Mechanism. J. Biol. Chem. 278 (27), 24469–24475. 10.1074/jbc.M301359200
Kishimoto S., Oka S., Gokoh M., Sugiura T. (2006). Chemotaxis of Human Peripheral Blood Eosinophils to 2-arachidonoylglycerol: Comparison with Other Eosinophil Chemoattractants. Int. Arch. Allergy Immunol. 140 Suppl 1 (Suppl. 1), 3–7. 10.1159/000092704
Kraft B., Kress H. G. (2005). Indirect CB2 Receptor and Mediator-dependent Stimulation of Human Whole-Blood Neutrophils by Exogenous and Endogenous Cannabinoids. J. Pharmacol. Exp. Ther. 315 (2), 641–647. 10.1124/jpet.105.084269
Kraft B., Wintersberger W., Kress H. G. (2004). Cannabinoid Receptor-independent Suppression of the Superoxide Generation of Human Neutrophils (PMN) by CP55 940, but Not by Anandamide. Life Sci. 75 (8), 969–977. 10.1016/j.lfs.2004.02.007
Kurihara R., Tohyama Y., Matsusaka S., Naruse H., Kinoshita E., Tsujioka T., et al. (2006). Effects of Peripheral Cannabinoid Receptor Ligands on Motility and Polarization in Neutrophil-like HL60 Cells and Human Neutrophils. J. Biol. Chem. 281 (18), 12908–12918. 10.1074/jbc.M510871200
Larose M. C., Archambault A. S., Provost V., Laviolette M., Flamand N. (2017). Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma. Front. Med. (Lausanne) 4, 136. 10.3389/fmed.2017.00136
Larose M. C., Turcotte C., Chouinard F., Ferland C., Martin C., Provost V., et al. (2014). Mechanisms of Human Eosinophil Migration Induced by the Combination of IL-5 and the Endocannabinoid 2-Arachidonoyl-Glycerol. J. Allergy Clin. Immunol. 133 (5), 1480–1483. 10.1016/j.jaci.2013.12.1081
Lee S. F., Newton C., Widen R., Friedman H., Klein T. W. (2001). Downregulation of Cannabinoid Receptor 2 (CB2) Messenger RNA Expression during In Vitro Stimulation of Murine Splenocytes with Lipopolysaccharide. Adv. Exp. Med. Biol. 493, 223–228. 10.1007/0-306-47611-8_26
Liebling P. D., Siu S. (2013). A Novel Cause of Eosinophilic Pneumonia: Recreational Marijuana Exposure. J. Bronchology Interv. Pulmonol 20 (2), 183–185. 10.1097/LBR.0b013e31828caa0d
Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., et al. (2005). The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Alpha Mediates the Anti-inflammatory Actions of Palmitoylethanolamide. Mol. Pharmacol. 67 (1), 15–19. 10.1124/mol.104.006353
Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. (1990). Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature 346 (6284), 561–564. 10.1038/346561a0
McHugh D., Tanner C., Mechoulam R., Pertwee R. G., Ross R. A. (2008). Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2. Mol. Pharmacol. 73 (2), 441–450. 10.1124/mol.107.041863
Montecucco F., Burger F., Mach F., Steffens S. (2008). CB2 Cannabinoid Receptor Agonist JWH-015 Modulates Human Monocyte Migration through Defined Intracellular Signaling Pathways. Am. J. Physiol. Heart Circ. Physiol. 294 (3), H1145–H1155. 10.1152/ajpheart.01328.2007
Montecucco F., Di Marzo V., da Silva R. F., Vuilleumier N., Capettini L., Lenglet S., et al. (2012). The Activation of the Cannabinoid Receptor Type 2 Reduces Neutrophilic Protease-Mediated Vulnerability in Atherosclerotic Plaques. Eur. Heart J. 33 (7), 846–856. 10.1093/eurheartj/ehr449
Mull E. S., Erdem G., Nicol K., Adler B., Shell R. (2020). Eosinophilic Pneumonia and Lymphadenopathy Associated with Vaping and Tetrahydrocannabinol Use. Pediatrics 145 (4). 10.1542/peds.2019-3007
Munro S., Thomas K. L., Abu-Shaar M. (1993). Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 365 (6441), 61–65. 10.1038/365061a0
Natarajan A., Shah P., Mirrakhimov A. E., Hussain N. (20132013). Eosinophilic Pneumonia Associated with Concomitant Cigarette and Marijuana Smoking. BMJ Case Rep.. 10.1136/bcr-2013-009001
Nilsson O., Fowler C. J., Jacobsson S. O. (2006). The Cannabinoid Agonist WIN 55,212-2 Inhibits TNF-Alpha-Induced Neutrophil Transmigration across ECV304 Cells. Eur. J. Pharmacol. 547 (1-3), 165–173. 10.1016/j.ejphar.2006.07.016
Öcal N., Doğan D., Çiçek A. F., Yücel O. E., Tozkoparan E. (2016). Acute Eosinophilic Pneumonia with Respiratory Failure Induced by Synthetic Cannabinoid Inhalation. Balkan Med. J. 33 (6), 688–690. 10.5152/balkanmedj.2016.151145
Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., et al. (2004). 2-arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces the Migration of EoL-1 Human Eosinophilic Leukemia Cells and Human Peripheral Blood Eosinophils. J. Leukoc. Biol. 76 (5), 1002–1009. 10.1189/jlb.0404252
Parlar A., Arslan S. O., Doğan M. F., Çam S. A., Yalçin A., Elibol E., et al. (2018). The Exogenous Administration of CB2 Specific Agonist, GW405833, Inhibits Inflammation by Reducing Cytokine Production and Oxidative Stress. Exp. Ther. Med. 16 (6), 4900–4908. 10.3892/etm.2018.6753
Pereira J. P., An J., Xu Y., Huang Y., Cyster J. G. (2009). Cannabinoid Receptor 2 Mediates the Retention of Immature B Cells in Bone Marrow Sinusoids. Nat. Immunol. 10 (4), 403–411. 10.1038/ni.1710
Raborn E. S., Jamerson M., Marciano-Cabral F., Cabral G. A. (2014). Cannabinoid Inhibits HIV-1 Tat-Stimulated Adhesion of Human Monocyte-like Cells to Extracellular Matrix Proteins. Life Sci. 104 (1-2), 15–23. 10.1016/j.lfs.2014.04.008
Rahaman O., Bhattacharya R., Liu C. S. C., Raychaudhuri D., Ghosh A. R., Bandopadhyay P., et al. (2019). Cutting Edge: Dysregulated Endocannabinoid-Rheostat for Plasmacytoid Dendritic Cell Activation in a Systemic Lupus Endophenotype. J. Immunol. 202 (6), 1674–1679. 10.4049/jimmunol.1801521
Ravi J., Elbaz M., Wani N. A., Nasser M. W., Ganju R. K. (2016). Cannabinoid Receptor-2 Agonist Inhibits Macrophage Induced EMT in Non-small Cell Lung Cancer by Downregulation of EGFR Pathway. Mol. Carcinog 55 (12), 2063–2076. 10.1002/mc.22451
Rayman N., Lam K. H., Laman J. D., Simons P. J., Löwenberg B., Sonneveld P., et al. (2004). Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status. J. Immunol. 172 (4), 2111–2117. 10.4049/jimmunol.172.4.2111
Rayman N., Lam K. H., Van Leeuwen J., Mulder A. H., Budel L. M., Löwenberg B., et al. (2007). The Expression of the Peripheral Cannabinoid Receptor on Cells of the Immune System and Non-Hodgkin's Lymphomas. Leuk. Lymphoma 48 (7), 1389–1399. 10.1080/10428190701377030
Rizzo M. D., Crawford R. B., Bach A., Sermet S., Amalfitano A., Kaminski N. E. (2019). Δ9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J. Pharmacol. Exp. Ther. 371 (1), 191–201. 10.1124/jpet.119.260661
Robinson R. H., Meissler J. J., Breslow-Deckman J. M., Gaughan J., Adler M. W., Eisenstein T. K. (2013). Cannabinoids Inhibit T-Cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction. J. Neuroimmune Pharmacol. 8 (5), 1239–1250. 10.1007/s11481-013-9485-1
Sánchez C., de Ceballos M. L., Gomez del Pulgar T., Rueda D., Corbacho C., Velasco G., et al. (2001). Inhibition of Glioma Growth In Vivo by Selective Activation of the CB(2) Cannabinoid Receptor. Cancer Res. 61 (15), 5784–5789.
Sánchez López A. J., Román-Vega L., Ramil Tojeiro E., Giuffrida A., García-Merino A. (2015). Regulation of Cannabinoid Receptor Gene Expression and Endocannabinoid Levels in Lymphocyte Subsets by Interferon-β: a Longitudinal Study in Multiple Sclerosis Patients. Clin. Exp. Immunol. 179 (1), 119–127. 10.1111/cei.12443
Sauvaget E., Dellamonica J., Arlaud K., Sanfiorenzo C., Bernardin G., Padovani B., et al. (2010). Idiopathic Acute Eosinophilic Pneumonia Requiring ECMO in a Teenager Smoking Tobacco and Cannabis. Pediatr. Pulmonol 45 (12), 1246–1249. 10.1002/ppul.21314
Soethoudt M., Grether U., Fingerle J., Grim T. W., Fezza F., de Petrocellis L., et al. (2017). Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased Signalling and Off-Target Activity. Nat. Commun. 8, 13958. 10.1038/ncomms13958
Staiano R. I., Loffredo S., Borriello F., Iannotti F. A., Piscitelli F., Orlando P., et al. (2016). Human Lung-Resident Macrophages Express CB1 and CB2 Receptors Whose Activation Inhibits the Release of Angiogenic and Lymphangiogenic Factors. J. Leukoc. Biol. 99 (4), 531–540. 10.1189/jlb.3HI1214-584R
Tanikawa T., Kurohane K., Imai Y. (2007). Induction of Preferential Chemotaxis of Unstimulated B-Lymphocytes by 2-arachidonoylglycerol in Immunized Mice. Microbiol. Immunol. 51 (10), 1013–1019. 10.1111/j.1348-0421.2007.tb03985.x
Tarique A. A., Evron T., Zhang G., Tepper M. A., Morshed M. M., Andersen I. S. G., et al. (2020). Anti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages from Cystic Fibrosis. J. Cyst Fibros 19 (5), 823–829. 10.1016/j.jcf.2020.03.015
Tiberi M., Evron T., Saracini S., Boffa L., Mercuri N. B., Chintalacharuvu S. R., et al. (2021). Potent T Cell-Mediated Anti-inflammatory Role of the Selective CB2 Agonist Lenabasum in Multiple Sclerosis. Neuropathol. Appl. Neurobiol..
Turcotte C., Blanchet M. R., Laviolette M., Flamand N. (2016). The CB2 Receptor and its Role as a Regulator of Inflammation. Cell Mol Life Sci 73 (23), 4449–4470. 10.1007/s00018-016-2300-4
Turcotte C., Chouinard F., Lefebvre J. S., Flamand N. (2015). Regulation of Inflammation by Cannabinoids, the Endocannabinoids 2-Arachidonoyl-Glycerol and Arachidonoyl-Ethanolamide, and Their Metabolites. J. Leukoc. Biol. 97 (6), 1049–1070. 10.1189/jlb.3RU0115-021R
Van Sickle M. D., Duncan M., Kingsley P. J., Mouihate A., Urbani P., Mackie K., et al. (2005). Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science 310 (5746), 329–332. 10.1126/science.1115740
Wang L. L., Zhao R., Li J. Y., Li S. S., Liu M., Wang M., et al. (2016). Pharmacological Activation of Cannabinoid 2 Receptor Attenuates Inflammation, Fibrogenesis, and Promotes Re-epithelialization during Skin Wound Healing. Eur. J. Pharmacol. 786, 128–136. 10.1016/j.ejphar.2016.06.006
Williams J. C., Appelberg S., Goldberger B. A., Klein T. W., Sleasman J. W., Goodenow M. M. (2014). Δ(9)-Tetrahydrocannabinol Treatment during Human Monocyte Differentiation Reduces Macrophage Susceptibility to HIV-1 Infection. J. Neuroimmune Pharmacol. 9 (3), 369–379. 10.1007/s11481-014-9527-3
Yuan M., Kiertscher S. M., Cheng Q., Zoumalan R., Tashkin D. P., Roth M. D. (2002). Delta 9-Tetrahydrocannabinol Regulates Th1/Th2 Cytokine Balance in Activated Human T Cells. J. Neuroimmunol 133 (1-2), 124–131. 10.1016/s0165-5728(02)00370-3
Zhao Y., Yuan Z., Liu Y., Xue J., Tian Y., Liu W., et al. (2010). Activation of Cannabinoid CB2 Receptor Ameliorates Atherosclerosis Associated with Suppression of Adhesion Molecules. J. Cardiovasc. Pharmacol. 55 (3), 292–298. 10.1097/FJC.0b013e3181d2644d
Zhou L., Zhou S., Yang P., Tian Y., Feng Z., Xie X. Q., et al. (2018). Targeted Inhibition of the Type 2 Cannabinoid Receptor Is a Novel Approach to Reduce Renal Fibrosis. Kidney Int. 94 (4), 756–772. 10.1016/j.kint.2018.05.023
Zhou X., Yang L., Fan X., Zhao X., Chang N., Yang L., et al. (2020). Neutrophil Chemotaxis and NETosis in Murine Chronic Liver Injury via Cannabinoid Receptor 1/Gαi/o/ROS/P38 MAPK Signaling Pathway. Cells 9 (2). 10.3390/cells9020373

Associated Data

Data Availability Statement

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

Studies

Conditions

Cannabinoids and active compounds

Related research

Abstract

Untitled section

Article notes

Untitled section

Author notes

Introduction

Expression of the CB1 and CB2 Receptors by Human Blood Leukocytes

Factors Influencing CB2 Receptor Expression in Human Leukocytes

Impact of CB2 Receptor Activation in Human Leukocytes

Human Eosinophils

Human B Lymphocytes

Human Neutrophils

Human T Lymphocytes

Human Monocytes

Human Macrophages

Human Mast Cells

Human Dendritic Cells

Conclusion

Acknowledgments

Data Availability Statement

Ethics Statement

Author Contributions

Funding

Conflict of Interest

Publisher’s Note

References

Untitled section

References

Associated Data

Data Availability Statement

Additional materials

Expression of the CB₁ and CB₂ Receptors by Human Blood Leukocytes

Factors Influencing CB₂ Receptor Expression in Human Leukocytes

Impact of CB₂ Receptor Activation in Human Leukocytes